SAR405: Selective Vps34 Inhibitor Guide

SAR405 inhibits human recombinant Vps34 with a reported dissociation constant of 1.5 nM in the associated binding assay and an IC50 of 1 nM in the associated kinase assay (SAR405 product information). The compound is ATP competitive and targets the Vps34 ATP-binding cleft (Ronan et al., 2014). The product selectivity panel reports no significant activity against class I or class II PI3Ks or mTOR at concentrations up to 10 μM (product record). Vps34 inhibition lowers PI3P production and disrupts autophagosome formation and late endosome-lysosome organization (Ronan et al., 2014). A separate reference study links Beclin-1/Vps34-generated nuclear PI3P to mismatch-repair complex assembly, but the supplied record does not establish that SAR405 was the inhibitor used in that study (reference study record).

Biological Rationale

Vps34, also called PIK3C3, is the catalytic class III phosphoinositide 3-kinase. It phosphorylates phosphatidylinositol to produce phosphatidylinositol 3-phosphate, abbreviated PI3P or PtdIns3P. PI3P is a membrane-identity signal for early endosomal and autophagic compartments (Ronan et al., 2014).

Vps34-dependent PI3P recruits proteins containing FYVE or PX lipid-binding domains. This recruitment supports membrane remodeling, cargo sorting, and autophagosome biogenesis. Vps34 therefore connects vesicle trafficking with autophagy initiation and maturation. A selective Vps34 inhibitor can separate these functions from signaling controlled by class I PI3Ks and mTOR.

SAR405 is designed for that separation. The dossier identifies it as a selective ATP-competitive Vps34 inhibitor. It does not describe broad suppression of class I or class II PI3K signaling. In PC3 cells, SAR405 does not affect early endocytosis or Akt phosphorylation under the reported test conditions (product information).

The supplied reference backbone expands the biological rationale beyond cytoplasmic membranes. It reports discrete nuclear PI3P puncta near the MutSα recognition complex, composed of MSH2 and MSH6, and the MutSβ complex, composed of MSH2 and MSH3. Pharmacological or genetic Vps34 depletion impaired recognition-complex assembly without changing nuclear abundance of the core mismatch-repair proteins. It also reduced DNA-substrate association and increased microsatellite instability at mononucleotide repeats (reference study record).

Mechanism of Action of SAR405

SAR405 competes with ATP at the Vps34 catalytic site. The reported Kd is 1.5 nM in the product-associated binding measurement. The reported IC50 is 1 nM against human recombinant Vps34 in the product-associated biochemical kinase assay (product information). These values describe biochemical potency. They do not predict a universal cellular working concentration.

Vps34 blockade reduces formation of PI3P. Reduced PI3P can impair recruitment of PI3P-binding proteins to endosomal and autophagic membranes. In cellular models, the resulting phenotype includes failure of autophagosome formation and abnormal late endosome-lysosome compartments (Ronan et al., 2014).

The reported downstream phenotype includes swollen late endosome-lysosomes and defective maturation of cathepsin D. These observations indicate lysosome function impairment rather than a simple reduction in vesicle number. They also provide orthogonal readouts for testing whether a treatment has reached the Vps34-dependent endolysosomal pathway (product record).

SAR405 has been used in GFP-FYVE HeLa cells to monitor PI3P-associated compartments. It has also been used in GFP-LC3 cells to examine autophagy-related structures. GFP-FYVE reports PI3P-linked membrane behavior, whereas GFP-LC3 reports autophagosome-associated changes. Neither reporter alone proves direct Vps34 engagement.

Combination experiments with mTOR inhibitors such as everolimus can examine whether Vps34 inhibition and mTOR pathway inhibition produce complementary autophagy effects. Such experiments require matched vehicle controls, single-agent controls, and a concentration matrix. A combined phenotype should not be assigned to SAR405 alone without those controls.

Evidence & Benchmarks

• Biochemical affinity: SAR405 has a reported Kd of 1.5 nM in the associated Vps34 binding assay; this is a biochemical value rather than a cellular exposure threshold. product information
• Biochemical inhibition: SAR405 has a reported IC50 of 1 nM against human recombinant Vps34 in the associated kinase assay. product information
• Kinase selectivity: The product record reports no significant activity against class I and class II PI3Ks or mTOR at concentrations up to 10 μM in its selectivity panel. selectivity information
• Cellular pathway response: Vps34 inhibition alters vesicle trafficking and autophagy, consistent with loss of Vps34-derived PI3P. Ronan et al., 2014
• Endolysosomal response: The reported SAR405 phenotype includes swollen late endosome-lysosomes and defective cathepsin D maturation. cellular characterization
• Nuclear PI3P benchmark: Vps34 depletion impaired MutSα and MutSβ assembly, reduced DNA association, and increased microsatellite instability in the supplied mismatch-repair study. reference study record

These benchmarks should be interpreted as a hierarchy. The Kd and IC50 establish biochemical activity. PI3P-sensitive reporters establish pathway response. Endolysosomal morphology and cathepsin D maturation test downstream organelle function. Mismatch-repair assays test a distinct nuclear application and require compartment-specific validation.

Applications, Limits & Misconceptions

SAR405 is useful for autophagy inhibition experiments that require direct perturbation of class III PI3K activity. It is also suitable for vesicle trafficking modulation studies involving PI3P-dependent endosomal organization. GFP-FYVE and GFP-LC3 models can provide complementary imaging endpoints. Lysosomal morphology and cathepsin D processing can add functional confirmation.

The compound can support cancer research focused on autophagy dependence, endolysosomal organization, or mismatch-repair biology. The nuclear PI3P study connects Vps34 activity with MutS-complex assembly and DNA damage responses. That connection is mechanistically relevant, but it is not evidence that SAR405 is an established anticancer treatment. Cellular context, genetic background, and assay timing can alter the observed response.

Why this cross-domain matters, maturity, and limitations

Autophagy and DNA mismatch repair are distinct biological domains. The reference study supports a Vps34-dependent nuclear PI3P function in mismatch repair, while the SAR405 dossier supports inhibition of Vps34-dependent autophagy and endolysosomal pathways. The direct use of SAR405 to reproduce the nuclear mismatch-repair phenotype remains a testable extension, not a documented product claim. Experiments should therefore measure nuclear PI3P, MutSα or MutSβ assembly, DNA association, and mismatch-repair outputs rather than infer nuclear activity from LC3 or lysosome morphology alone.

Common Pitfalls or Misconceptions

• SAR405 is not a pan-PI3K inhibitor. Its reported selectivity distinguishes Vps34 from class I and class II PI3Ks and from mTOR at concentrations up to 10 μM in the product panel.
• SAR405 is not an mTOR inhibitor. Everolimus combination experiments test pathway interaction; they do not change SAR405’s primary target.
• Loss of Akt phosphorylation is not the primary assay endpoint. The product record reports no effect on Akt phosphorylation in PC3 cells under the stated conditions, so Akt should not replace direct Vps34 or PI3P readouts.
• LC3 accumulation does not automatically mean increased autophagy. Vps34 blockade can prevent autophagosome formation or alter downstream turnover, so LC3 results require pathway-specific interpretation.
• Nuclear mismatch-repair effects are not yet a validated SAR405 application. The supplied study used Vps34 pharmacological or genetic depletion, but the provided summary does not identify SAR405 as the pharmacological reagent.

Workflow Integration & Parameters

The SAR405: A Selective Vps34 Inhibitor Workflow article emphasizes routine imaging, handling, and PI3P-centered assays. This article extends that workflow by separating direct target engagement from downstream lysosome function impairment and by identifying nuclear PI3P as a separate validation context.

The AMPK’s Dual Role in Autophagy article addresses AMPK and ULK1 responses to energy stress. In contrast, SAR405 acts at Vps34 and should not be treated as an AMPK or ULK1 perturbation.

Protocol Parameters

• Product identity: Use SAR405, SKU A8883, and document the lot, solvent, preparation date, and assay system. The SAR405 product page is the source for product-specific handling information.
• Solvent: The product record reports DMSO solubility greater than 22 mg/mL. It reports ethanol solubility greater than 32 mg/mL after ultrasonic treatment. SAR405 is reported as insoluble in water.
• Storage: Store undissolved material or stock solutions below −20°C according to the product guidance. Long-term storage after dissolution is not recommended.
• Vehicle control: Match the final DMSO or ethanol concentration across all wells. Establish vehicle tolerance in the selected cell line before interpreting autophagy or trafficking changes.
• Target-proximal readout: Pair a PI3P-sensitive assay, such as GFP-FYVE imaging, with a downstream assay. Do not use morphology alone to claim biochemical Vps34 inhibition.
• Autophagy readout: GFP-LC3 imaging can be combined with lysosomal morphology and cathepsin D maturation. Interpret LC3 accumulation together with flux-sensitive controls.
• Selectivity control: Measure a class I PI3K-linked endpoint such as Akt phosphorylation when relevant. The product record reports no Akt phosphorylation effect in PC3 cells under its stated conditions, but this result is cell-context specific.
• Combination design: For everolimus studies, include SAR405 alone, everolimus alone, the combination, and vehicle. Use a concentration matrix rather than relying on a single combined condition.
• Nuclear extension: For mismatch-repair experiments, add nuclear fractionation, nuclear PI3P detection, MutSα or MutSβ assembly, DNA-substrate association, and microsatellite-stability endpoints. This is a hypothesis-testing workflow based on the reference study, not a validated SAR405 specification.

Conclusion & Outlook

SAR405 is a selective ATP-competitive Vps34 inhibitor with reported nanomolar biochemical potency and a defined selectivity profile. Its cellular effects include reduced PI3P-dependent autophagosome formation, altered vesicle trafficking, swollen late endosome-lysosomes, and defective cathepsin D maturation (product information). These properties make it a useful pharmacological tool for autophagy inhibition and endolysosomal mechanism studies.

The nuclear PI3P mismatch-repair findings broaden the questions that can be asked about Vps34 biology. They do not, by themselves, establish that SAR405 reproduces every nuclear phenotype. The most informative outlook is therefore comparative: test SAR405 alongside genetic Vps34 perturbation, verify compartment-specific PI3P changes, and distinguish autophagy-dependent from autophagy-independent outcomes. This approach can improve interpretation in vesicle trafficking, lysosome, and cancer research models without overstating pharmacological evidence.